TG-C: A Potential Breakthrough in Osteoarthritis treatment?

At the recent International Society of Osteoarthritis Research (OARSI) conference held in Songdo,Incheon,Kolon Tea Shujin presented compelling data supporting the safety and efficacy of their osteoarthritis cell gene therapy,TG-C. the findings suggest that TG-C could potentially delay or even replace the need for artificial joint surgery in patients suffering from knee osteoarthritis.

Long-Term Safety Confirmed

A key highlight of the presentation was the long-term safety data derived from a U.S. Long-Term Study (LTS). Over a 15-year monitoring period, no tumor-related adverse events were observed in patients treated with TG-C. Moreover,when compared to the average cancer incidence rates within the U.S. population for similar age groups, the incidence of cancer among TG-C clinical trial participants was notably lower. This data provides a strong foundation for establishing the safety profile of this novel therapy.

Delaying or Replacing Knee Replacement Surgery: A Promising Outcome

Beyond safety,the data also indicated a significant impact on the progression of osteoarthritis. By comparing data from a National Institutes of Health (NIH) osteoarthritis project, which tracked 595 patients over 11 years, with data from TG-C clinical trial participants, researchers observed a notable difference in the need for knee replacement surgery.

The NIH project revealed that 15.5% of osteoarthritis patients required knee replacement surgery within 5.1 years of disease onset. In contrast, only 7.0% of patients who participated in the TG-C clinical trials underwent knee replacement surgery. Moreover, the time to surgery was extended to 5.7 years from the initial diagnosis in the TG-C group. This suggests that TG-C may not only reduce the likelihood of needing surgery but also postpone the procedure for those who eventually require it.

The Importance of DMOADs in Osteoarthritis Treatment

TG-C is being investigated as a potential Disease-Modifying Osteoarthritis Drug (DMOAD). Currently, most osteoarthritis treatments focus on managing symptoms like pain and inflammation. DMOADs, however, aim to address the underlying causes of the disease, potentially slowing down or even reversing its progression. If TG-C proves to be an effective DMOAD, it could revolutionize the treatment landscape for osteoarthritis, offering patients a chance to maintain joint health and mobility for longer.

The global osteoarthritis therapeutics market is projected to reach $12.6 billion by 2027, driven by an aging population and increasing prevalence of obesity, both significant risk factors for the disease. The growth of effective DMOADs like TG-C is crucial to addressing this growing healthcare challenge.

Looking Ahead

The data presented by Kolon Tea Shujin at OARSI offers a glimmer of hope for individuals suffering from osteoarthritis. While further research and clinical trials are necessary, the initial findings suggest that TG-C holds significant promise as a safe and effective treatment option that could potentially transform the management of this debilitating condition.

We are pleased to introduce TG-C’s meaningful data in OARSI, which is held for the first time in Korea.

Representative of Kolon Tea Shujin